Dexamethasone Suppresses IL-33-exacerbated Malignant Phenotype of U87MG
Glioblastoma Cells via NF-κB and MAPK Signaling Pathways

Jie      Ai; Yinhua      Weng; Liyan      Jiang; Chao      Liu; Hongbo      Liu; Huoying      Chen

doi:10.2174/0118715206281991231222073858

Abstract

Background: Interleukin (IL)-33 is highly expressed in glioblastoma (GBM) and promotes tumor progression. Targeting IL-33 may be an effective strategy for the treatment of GBM. Dexamethasone (DEX) is a controversial drug routinely used clinically in GBM therapy. Whether DEX has an effect on IL-33 is unknown. This study aimed to investigate the effect of DEX on IL-33 and the molecular mechanisms involved.

Methods: U87MG cells were induced by tumor necrosis factor (TNF)-α to express IL-33 and then treated with DEX. The mRNA levels of IL-33, NF-κB p65, ERK1/2, and p38 were determined by real-time quantitative PCR. The expression of IL-33, IkBα (a specific inhibitor of NF-κB) and MKP-1 (a negative regulator of MAPK), as well as the phosphorylation of NF-κB, ERK1/2 and p38 MAPK, were detected by Western blotting. The secretion of IL-33 was measured by ELISA. The proliferation, migration and invasion of U87MG cells were detected by CCK8 and transwell assays, respectively.

Results: DEX significantly reduced TNF-α-induced production of IL-33 in U87MG cells, which was dependent on inhibiting the activation of the NF-κB, ERK1/2 and p38 MAPK signaling pathways, and was accompanied by the increased expression of IkBα but not MKP-1. Furthermore, the proliferation, migration and invasion of U87MG cells exacerbated by IL-33 were suppressed by DEX.

Conclusion: DEX inhibited the production and tumor-promoting function of IL-33. Whether DEX can benefit GBM patients remains controversial. Our results suggest that GBM patients with high IL-33 expression may benefit from DEX treatment and deserve further investigation.

« Previous Next »

Graphical Abstract

[1]
Xu, S.; Tang, L.; Li, X.; Fan, F.; Liu, Z. Immunotherapy for glioma: Current management and future application. Cancer Lett.,  2020, 476, 1-12.
 [http://dx.doi.org/10.1016/j.canlet.2020.02.002] [PMID: 32044356]

[2]
Stupp, R.; Mason, W.P.; van den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.B.; Belanger, K.; Brandes, A.A.; Marosi, C.; Bogdahn, U.; Curschmann, J.; Janzer, R.C.; Ludwin, S.K.; Gorlia, T.; Allgeier, A.; Lacombe, D.; Cairncross, J.G.; Eisenhauer, E.; Mirimanoff, R.O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.,  2005, 352(10), 987-996.
 [http://dx.doi.org/10.1056/NEJMoa043330] [PMID: 15758009]

[3]
Stupp, R.; Hegi, M.E.; Mason, W.P.; van den Bent, M.J.; Taphoorn, M.J.B.; Janzer, R.C.; Ludwin, S.K.; Allgeier, A.; Fisher, B.; Belanger, K.; Hau, P.; Brandes, A.A.; Gijtenbeek, J.; Marosi, C.; Vecht, C.J.; Mokhtari, K.; Wesseling, P.; Villa, S.; Eisenhauer, E.; Gorlia, T.; Weller, M.; Lacombe, D.; Cairncross, J.G.; Mirimanoff, R.O. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol.,  2009, 10(5), 459-466.
 [http://dx.doi.org/10.1016/S1470-2045(09)70025-7] [PMID: 19269895]

[4]
Cayrol, C.; Girard, J.P. Interleukin-33 (IL -33): A nuclear cytokine from the IL -1 family. Immunol. Rev.,  2018, 281(1), 154-168.
 [http://dx.doi.org/10.1111/imr.12619] [PMID: 29247993]

[5]
Roussel, L.; Erard, M.; Cayrol, C.; Girard, J.P. Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A–H2B acidic pocket. EMBO Rep.,  2008, 9(10), 1006-1012.
 [http://dx.doi.org/10.1038/embor.2008.145] [PMID: 18688256]

[6]
Ali, S.; Mohs, A.; Thomas, M.; Klare, J.; Ross, R.; Schmitz, M.L.; Martin, M.U. The dual function cytokine IL-33 interacts with the transcription factor NF-κB to dampen NF-κB-stimulated gene transcription. J. Immunol.,  2011, 187(4), 1609-1616.
 [http://dx.doi.org/10.4049/jimmunol.1003080] [PMID: 21734074]

[7]
Drake, L.Y.; Kita, H. IL -33: Biological properties, functions, and roles in airway disease. Immunol. Rev.,  2017, 278(1), 173-184.
 [http://dx.doi.org/10.1111/imr.12552] [PMID: 28658560]

[8]
Fairlie-Clarke, K.; Barbour, M.; Wilson, C.; Hridi, S.U.; Allan, D.; Jiang, H.R. Expression and function of IL-33/ST2 axis in the central nervous system under normal and diseased conditions. Front. Immunol.,  2018, 9, 2596.
 [http://dx.doi.org/10.3389/fimmu.2018.02596] [PMID: 30515150]

[9]
Dohi, E.; Choi, E.Y.; Rose, I.V.L.; Murata, A.S.; Chow, S.; Niwa, M.; Kano, S. Behavioral changes in mice lacking interleukin-33. eNeuro,  2017, , 4.(6) ENEURO.0147-17.2017.
 [http://dx.doi.org/10.1523/ENEURO.0147-17.2017] [PMID: 29379874]

[10]
Vainchtein, I.D.; Chin, G.; Cho, F.S.; Kelley, K.W.; Miller, J.G.; Chien, E.C.; Liddelow, S.A.; Nguyen, P.T.; Nakao-Inoue, H.; Dorman, L.C.; Akil, O.; Joshita, S.; Barres, B.A.; Paz, J.T.; Molofsky, A.B.; Molofsky, A.V. Astrocyte-derived interleukin-33 promotes microglial synapse engulfment and neural circuit development. Science,  2018, 359(6381), 1269-1273.
 [http://dx.doi.org/10.1126/science.aal3589] [PMID: 29420261]

[11]
Zhang, J.; Tao, T.; Wang, K.; Zhang, G.; Yan, Y.; Lin, H.; Li, Y.; Guan, M.; Yu, J.; Wang, X. IL-33/ST2 axis promotes glioblastoma cell invasion by accumulating tenascin-C. Sci. Rep.,  2019, 9(1), 20276.
 [http://dx.doi.org/10.1038/s41598-019-56696-1] [PMID: 31889095]

[12]
De Boeck, A.; Ahn, B.Y.; D’Mello, C.; Lun, X.; Menon, S.V.; Alshehri, M.M.; Szulzewsky, F.; Shen, Y.; Khan, L.; Dang, N.H.; Reichardt, E.; Goring, K.A.; King, J.; Grisdale, C.J.; Grinshtein, N.; Hambardzumyan, D.; Reilly, K.M.; Blough, M.D.; Cairncross, J.G.; Yong, V.W.; Marra, M.A.; Jones, S.J.M.; Kaplan, D.R.; McCoy, K.D.; Holland, E.C.; Bose, P.; Chan, J.A.; Robbins, S.M.; Senger, D.L. Glioma-derived IL-33 orchestrates an inflammatory brain tumor microenvironment that accelerates glioma progression. Nat. Commun.,  2020, 11(1), 4997.
 [http://dx.doi.org/10.1038/s41467-020-18569-4] [PMID: 33020472]

[13]
Lin, L.; Li, Y.; Liu, M.; Li, Q.; Liu, Q.; Li, R. The Interleukin-33/ST2 axis promotes glioma mesenchymal transition, stemness and TMZ resistance via JNK activation. Aging,  2020, 12(2), 1685-1703.
 [http://dx.doi.org/10.18632/aging.102707] [PMID: 32003751]

[14]
Cenciarini, M.; Valentino, M.; Belia, S.; Sforna, L.; Rosa, P.; Ronchetti, S.; D’Adamo, M.C.; Pessia, M. Dexamethasone in glioblastoma multiforme therapy: Mechanisms and controversies. Front. Mol. Neurosci.,  2019, 12, 65.
 [http://dx.doi.org/10.3389/fnmol.2019.00065] [PMID: 30983966]

[15]
Zhou, X.; Jin, X. Dexamethasone inhibits IL-33 expression in the lung in a rat model of Aspergillus fumigatus-exposed bronchial asthma. Fudan Univ. J. Medical Sci.,  2017, 44, 326-332.

[16]
Paranjape, A.; Chernushevich, O.; Qayum, A.A.; Spence, A.J.; Taruselli, M.T.; Abebayehu, D.; Barnstein, B.O.; McLeod, J.J.A.; Baker, B.; Bajaj, G.S.; Chumanevich, A.P.; Oskeritzian, C.A.; Ryan, J.J. Dexamethasone rapidly suppresses IL-33-stimulated mast cell function by blocking transcription factor activity. J. Leukoc. Biol.,  2016, 100(6), 1395-1404.
 [http://dx.doi.org/10.1189/jlb.3A0316-125R] [PMID: 27443878]

[17]
Wang, H.; Li, M.; Rinehart, J.J.; Zhang, R. Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: In vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy. Clin. Cancer Res.,  2004, 10(5), 1633-1644.
 [http://dx.doi.org/10.1158/1078-0432.CCR-0829-3] [PMID: 15014014]

[18]
Wang, H.; Wang, Y.; Rayburn, E.; Hill, D.; Rinehart, J.; Zhang, R. Dexamethasone as a chemosensitizer for breast cancer chemotherapy: Potentiation of the antitumor activity of adriamycin, modulation of cytokine expression, and pharmacokinetics. Int. J. Oncol.,  2007, 30(4), 947-953.
 [http://dx.doi.org/10.3892/ijo.30.4.947] [PMID: 17332934]

[19]
Zhang, Y.; Shi, G.; Zhang, H.; Xiong, Q.; Cheng, F.; Wang, H.; Luo, J.; Zhang, Y.; Shi, P.; Xu, J.; Fu, J.; Chen, N.; Cheng, L.; Li, Y.; Dai, L.; Yang, Y.; Yu, D.; Zhang, S.; Deng, H. Dexamethasone enhances the lung metastasis of breast cancer via a PI3K-SGK1-CTGF pathway. Oncogene,  2021, 40(35), 5367-5378.
 [http://dx.doi.org/10.1038/s41388-021-01944-w] [PMID: 34272474]

[20]
Price, L.C.; Shao, D.; Meng, C.; Perros, F.; Garfield, B.E.; Zhu, J.; Montani, D.; Dorfmuller, P.; Humbert, M.; Adcock, I.M.; Wort, S.J. Dexamethasone induces apoptosis in pulmonary arterial smooth muscle cells. Respir. Res.,  2015, 16(1), 114.
 [http://dx.doi.org/10.1186/s12931-015-0262-y] [PMID: 26382031]

[21]
Lea, S.; Li, J.; Plumb, J.; Gaffey, K.; Mason, S.; Gaskell, R.; Harbron, C.; Singh, D. P38 MAPK and glucocorticoid receptor crosstalk in bronchial epithelial cells. J. Mol. Med.,  2020, 98(3), 361-374.
 [http://dx.doi.org/10.1007/s00109-020-01873-3] [PMID: 31974640]

[22]
Zhang, J.F.; Wang, P.; Yan, Y.J.; Li, Y.; Guan, M.W.; Yu, J.J.; Wang, X.D. IL-33 enhances glioma cell migration and invasion by upregulation of MMP2 and MMP9 via the ST2-NF-κB pathway. Oncol. Rep.,  2017, 38(4), 2033-2042.
 [http://dx.doi.org/10.3892/or.2017.5926] [PMID: 28849217]

[23]
Marvie, P.; Lisbonne, M.; L’Helgoualc’h, A.; Rauch, M.; Turlin, B.; Preisser, L.; Bourd-Boittin, K.; Théret, N.; Gascan, H.; Piquet-Pellorce, C.; Samson, M. Interleukin-33 overexpression is associated with liver fibrosis in mice and humans. J. Cell. Mol. Med.,  2010, 14(6b), 1726-1739.
 [http://dx.doi.org/10.1111/j.1582-4934.2009.00801.x] [PMID: 19508382]

[24]
Chen, H.; Sun, Y.; Lai, L.; Wu, H.; Xiao, Y.; Ming, B.; Gao, M.; Zou, H.; Xiong, P.; Xu, Y.; Tan, Z.; Gong, F.; Zheng, F. Interleukin-33 is released in spinal cord and suppresses experimental autoimmune encephalomyelitis in mice. Neuroscience,  2015, 308, 157-168.
 [http://dx.doi.org/10.1016/j.neuroscience.2015.09.019] [PMID: 26363151]

[25]
Zhou, Q.; Wu, X.; Wang, X.; Yu, Z.; Pan, T.; Li, Z.; Chang, X.; Jin, Z.; Li, J.; Zhu, Z.; Liu, B.; Su, L. The reciprocal interaction between tumor cells and activated fibroblasts mediated by TNF-α/IL-33/ST2L signaling promotes gastric cancer metastasis. Oncogene,  2020, 39(7), 1414-1428.
 [http://dx.doi.org/10.1038/s41388-019-1078-x] [PMID: 31659258]

[26]
Kempuraj, D.; Thangavel, R.; Selvakumar, G.P.; Ahmed, M.E.; Zaheer, S.; Raikwar, S.P.; Zahoor, H.; Saeed, D.; Dubova, I.; Giler, G.; Herr, S.; Iyer, S.S.; Zaheer, A. Mast cell proteases activate astrocytes and glia-neurons and release interleukin-33 by activating p38 and ERK1/2 MAPKs and NF-κB.  Mol. Neurobiol.,  2019, 56(3), 1681-1693.
 [http://dx.doi.org/10.1007/s12035-018-1177-7] [PMID: 29916143]

[27]
Rodriguez, M.S.; Thompson, J.; Hay, R.T.; Dargemont, C. Nuclear retention of IkappaBalpha protects it from signal-induced degradation and inhibits nuclear factor kappaB transcriptional activation. J. Biol. Chem.,  1999, 274(13), 9108-9115.
 [http://dx.doi.org/10.1074/jbc.274.13.9108] [PMID: 10085161]

[28]
Wu, W.; Pew, T.; Zou, M.; Pang, D.; Conzen, S.D. Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival. J. Biol. Chem.,  2005, 280(6), 4117-4124.
 [http://dx.doi.org/10.1074/jbc.M411200200] [PMID: 15590693]

[29]
Jang, B.C.; Lim, K.J.; Suh, M.H.; Park, J.G.; Suh, S.I. Dexamethasone suppresses interleukin-1Î2-induced human Î2-defensin 2 mRNA expression: Involvement of p38 MAPK, JNK, MKP-1, and NF-ÎºB transcriptional factor in A549 cells. FEMS Immunol. Med. Microbiol.,  2007, 51(1), 171-184.
 [http://dx.doi.org/10.1111/j.1574-695X.2007.00293.x] [PMID: 17645739]

[30]
Li, Q.; Valerio, M.S.; Kirkwood, K.L. MAPK usage in periodontal disease progression. J. Signal Transduct.,  2012, 2012, 1-17.
 [http://dx.doi.org/10.1155/2012/308943] [PMID: 22315682]

[31]
Fang, K.M.; Yang, C.S.; Lin, T.C.; Chan, T.C.; Tzeng, S.F. Induced interleukin-33 expression enhances the tumorigenic activity of rat glioma cells. Neuro-oncol.,  2014, 16(4), 552-566.
 [http://dx.doi.org/10.1093/neuonc/not234] [PMID: 24327583]

[32]
Akcora-Yildiz, D.; Yukselten, Y.; Sunguroglu, M.; Ugur, H.C.; Sunguroglu, A. IL-33 induces ADAMTS5 expression and cell migration in glioblastoma multiforme. Med. Oncol.,  2022, 39(2), 22.
 [http://dx.doi.org/10.1007/s12032-021-01590-y] [PMID: 34982269]

[33]
Zhou, X.; Feng, Y.; Liu, S.; Li, C.; Teng, Y.; Li, X.; Lu, J. IL-33 promotes the growth of non-small cell lung cancer cells through regulating miR-128-3p/CDIP1 signalling pathway. Cancer Manag. Res.,  2021, 13, 2379-2388.
 [http://dx.doi.org/10.2147/CMAR.S276297] [PMID: 33737835]

[34]
Askoura, M.; Abbas, H.A.; Al Sadoun, H.; Abdulaal, W.H.; Abu Lila, A.S.; Almansour, K.; Alshammari, F.; Khafagy, E.S.; Ibrahim, T.S.; Hegazy, W.A.H. Elevated levels of IL-33, IL-17 and IL-25 indicate the progression from chronicity to hepatocellular carcinoma in hepatitis C virus patients. Pathogens,  2022, 11(1), 57.
 [http://dx.doi.org/10.3390/pathogens11010057] [PMID: 35056005]

[35]
Landskron, G.; De la Fuente López, M.; Dubois-Camacho, K.; Díaz-Jiménez, D.; Orellana-Serradell, O.; Romero, D.; Sepúlveda, S.A.; Salazar, C.; Parada-Venegas, D.; Quera, R.; Simian, D.; González, M.J.; López-Köstner, F.; Kronberg, U.; Abedrapo, M.; Gallegos, I.; Contreras, H.R.; Peña, C.; Díaz-Araya, G.; Roa, J.C.; Hermoso, M.A. Interleukin 33/ST2 axis components are associated to desmoplasia, a metastasis-related factor in colorectal cancer. Front. Immunol.,  2019, 10, 1394.
 [http://dx.doi.org/10.3389/fimmu.2019.01394] [PMID: 31281317]

[36]
Huang, N.; Cui, X.; Li, W.; Zhang, C.; Liu, L.; Li, J. IL 33/ST2 promotes the malignant progression of gastric cancer via the MAPK pathway. Mol. Med. Rep.,  2021, 23(5), 361.
 [http://dx.doi.org/10.3892/mmr.2021.12000] [PMID: 33760194]

[37]
Hu, H.; Sun, J.; Wang, C.; Bu, X.; Liu, X.; Mao, Y.; Wang, H. IL-33 facilitates endocrine resistance of breast cancer by inducing cancer stem cell properties. Biochem. Biophys. Res. Commun.,  2017, 485(3), 643-650.
 [http://dx.doi.org/10.1016/j.bbrc.2017.02.080] [PMID: 28216163]

[38]
Gramatzki, D.; Frei, K.; Cathomas, G.; Moch, H.; Weller, M.; Mertz, K.D. Interleukin-33 in human gliomas: Expression and prognostic significance. Oncol. Lett.,  2016, 12(1), 445-452.
 [http://dx.doi.org/10.3892/ol.2016.4626] [PMID: 27347163]

[39]
Zhang, J.; Wang, P.; Ji, W.; Ding, Y.; Lu, X. Overexpression of interleukin-33 is associated with poor prognosis of patients with glioma. Int. J. Neurosci.,  2017, 127(3), 210-217.
 [http://dx.doi.org/10.1080/00207454.2016.1175441] [PMID: 27050560]

[40]
Calvén, J.; Akbarshahi, H.; Menzel, M.; Ayata, C.K.; Idzko, M.; Bjermer, L.; Uller, L. Rhinoviral stimuli, epithelial factors and ATP signalling contribute to bronchial smooth muscle production of IL-33. J. Transl. Med.,  2015, 13(1), 281.
 [http://dx.doi.org/10.1186/s12967-015-0645-3] [PMID: 26318341]

[41]
Li, Y.; Li, X.; Zhou, W.; Yu, Q.; Lu, Y. ORMDL3 modulates airway epithelial cell repair in children with asthma under glucocorticoid treatment via regulating IL-33. Pulm. Pharmacol. Ther.,  2020, 64, 101963.
 [http://dx.doi.org/10.1016/j.pupt.2020.101963] [PMID: 33035699]

[42]
Kabata, H.; Moro, K.; Fukunaga, K.; Suzuki, Y.; Miyata, J.; Masaki, K.; Betsuyaku, T.; Koyasu, S.; Asano, K. Thymic stromal lymphopoietin induces corticosteroid resistance in natural helper cells during airway inflammation. Nat. Commun.,  2013, 4(1), 2675.
 [http://dx.doi.org/10.1038/ncomms3675] [PMID: 24157859]

[43]
Li, W.; Yin, N.; Tao, W.; Wang, Q.; Fan, H.; Wang, Z. Berberine suppresses IL-33-induced inflammatory responses in mast cells by inactivating NF-κB and p38 signaling. Int. Immunopharmacol.,  2019, 66, 82-90.
 [http://dx.doi.org/10.1016/j.intimp.2018.11.009] [PMID: 30445310]

[44]
Xu, Y.; Liu, Q.; Guo, X.; Xiang, L.; Zhao, G. Resveratrol attenuates IL 33 induced mast cell inflammation associated with inhibition of NF κB activation and the P38 signaling pathway. Mol. Med. Rep.,  2020, 21(3), 1658-1666.
 [http://dx.doi.org/10.3892/mmr.2020.10952] [PMID: 32016471]

[45]
Bawazeer, M.A.; Theoharides, T.C. IL-33 stimulates human mast cell release of CCL5 and CCL2 via MAPK and NF-κB, inhibited by methoxyluteolin. Eur. J. Pharmacol.,  2019, 865, 172760.
 [http://dx.doi.org/10.1016/j.ejphar.2019.172760] [PMID: 31669588]

[46]
Colombo, B.B.; Fattori, V.; Guazelli, C.F.S.; Zaninelli, T.H.; Carvalho, T.T.; Ferraz, C.R.; Bussmann, A.J.C.; Ruiz-Miyazawa, K.W.; Baracat, M.M.; Casagrande, R.; Verri, W.A. Jr Vinpocetine ameliorates acetic acid-induced colitis by inhibiting NF-κB activation in mice. Inflammation,  2018, 41(4), 1276-1289.
 [http://dx.doi.org/10.1007/s10753-018-0776-9] [PMID: 29633103]

[47]
Fan, Z.; Sehm, T.; Rauh, M.; Buchfelder, M.; Eyupoglu, I.Y.; Savaskan, N.E. Dexamethasone alleviates tumor-associated brain damage and angiogenesis. PLoS One,  2014, 9(4), e93264.
 [http://dx.doi.org/10.1371/journal.pone.0093264] [PMID: 24714627]

[48]
Kaup, B.; Schindler, I.; Knüpfer, H.; Schlenzka, A.; Preiβ, R.; Knüpfer, M.M. Time-dependent inhibition of glioblastoma cell proliferation by dexamethasone. J. Neurooncol.,  2001, 51(2), 105-110.
 [http://dx.doi.org/10.1023/A:1010684921099] [PMID: 11386406]

[49]
Bauman, G.S.; MacDonald, W.; Moore, E.; Ramsey, D.A.; Fisher, B.J.; Amberger, V.R.; Del Maestro, R.M. Effects of radiation on a model of malignant glioma invasion. J. Neurooncol.,  1999, 44(3), 223-231.
 [http://dx.doi.org/10.1023/A:1006319417077] [PMID: 10720202]

[50]
Luedi, M.M.; Singh, S.K.; Mosley, J.C.; Hassan, I.S.A.; Hatami, M.; Gumin, J.; Andereggen, L.; Sulman, E.P.; Lang, F.F.; Stueber, F.; Fuller, G.N.; Colen, R.R.; Zinn, P.O. Dexamethasone-mediated oncogenicity in vitro and in an animal model of glioblastoma. J. Neurosurg.,  2018, 129(6), 1446-1455.
 [http://dx.doi.org/10.3171/2017.7.JNS17668] [PMID: 29328002]

[51]
Gündisch, S.; Boeckeler, E.; Behrends, U.; Amtmann, E.; Ehrhardt, H.; Jeremias, I. Glucocorticoids augment survival and proliferation of tumor cells. Anticancer Res.,  2012, 32(10), 4251-4261.
 [PMID: 23060545]

Rights & Permissions Print Cite

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/0118715206281991231222073858	Print ISSN 1871-5206
Publisher Name Bentham Science Publisher	Online ISSN 1875-5992

Anti-Cancer Agents in Medicinal Chemistry

Dexamethasone Suppresses IL-33-exacerbated Malignant Phenotype of U87MG Glioblastoma Cells via NF-κB and MAPK Signaling Pathways

Abstract Play Pause

Graphical Abstract

Related Journals

Related Books

Abstract